MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Acorda Therapeutics Company Profile (NASDAQ:ACOR)

Consensus Ratings for Acorda Therapeutics (NASDAQ:ACOR) (?)
Ratings Breakdown: 1 Sell Rating(s), 5 Hold Rating(s), 3 Buy Rating(s)
Consensus Rating:Hold (Score: 2.22)
Consensus Price Target: $39.75 (57.49% upside)

Analysts' Ratings History for Acorda Therapeutics (NASDAQ:ACOR)
Show:
DateFirmActionRatingPrice TargetActions
6/1/2016AegisBoost Price TargetBuy$40.00 -> $52.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/22/2016Leerink SwannReiterated RatingHold$31.00 -> $29.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/20/2016Cowen and CompanyReiterated RatingOutperform$65.00 -> $60.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/20/2016Evercore ISIReiterated RatingHold$32.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/30/2016Goldman SachsInitiated CoverageSell$23.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/14/2016Stifel NicolausLower Price TargetBuy$48.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/11/2016JPMorgan Chase & Co.Reiterated RatingNeutralView Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/31/2015Raymond JamesInitiated CoverageMarket PerformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/31/2015Canaccord GenuityReiterated RatingHold$32.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/22/2015MLV & Co.Set Price TargetBuy$58.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/9/2015GuggenheimInitiated CoverageNeutralView Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/22/2015Piper JaffrayInitiated CoverageNeutralView Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/13/2015Citigroup Inc.Reiterated RatingHold$46.00 -> $42.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/11/2015RBC CapitalSet Price TargetBuy$45.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/31/2014FBR & Co.Reiterated RatingOutperform$57.00 -> $59.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/30/2014MKM PartnersBoost Price TargetNeutral$31.50 -> $33.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/25/2014 forward)
Earnings History for Acorda Therapeutics (NASDAQ:ACOR)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
7/28/2016        
4/28/2016Q116$0.08$0.07$115.36 million$115.90 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/11/2016Q415$0.22$0.28$128.24 million$130.90 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/22/2015Q315$0.15$0.31$115.52 million$148.20 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/30/2015Q215$0.17$0.31$110.84 million$113.70 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/30/2015Q115$0.03($0.02)$100.20 million$99.85 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/12/2015Q414$0.14$0.46$110.80 million$117.90 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/30/2014Q314$0.05$0.28$94.70 million$106.00 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/31/2014Q214$0.15$0.42$91.40 million$97.13 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/6/2014Q114$0.09$0.21$81.30 million$80.52 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/19/2014Q413$0.18$0.32$89.96 million$92.59 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/31/2013Q313$0.13$0.36$90.01 million$84.92 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/1/2013Q2 2013$0.09$0.25$82.57 million$87.05 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/2/2013Q1 2013$0.20$0.09$80.77 million$71.90 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/13/2013Q4 2012$0.15$0.24$78.90 million$81.47 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/31/2012Q312$0.10$0.38$75.20 million$77.44 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/31/2012$0.27$0.27ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/3/2012$0.27$0.36ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/16/2012$0.24$0.40ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/4/2011$0.82$0.47ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/1/2011$0.10$0.01ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/5/2011$0.17($0.02)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/17/2011$0.17$0.09ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for Acorda Therapeutics (NASDAQ:ACOR)
No earnings estimates for this company have been tracked by MarketBeat.com

Dividend History for Acorda Therapeutics (NASDAQ:ACOR)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Acorda Therapeutics (NASDAQ:ACOR)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
6/22/2016David LawrenceInsiderSell500$25.09$12,545.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/8/2016Steven M RauscherDirectorSell1,086$27.83$30,223.38View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/13/2016Andrew A HindmanInsiderSell4,860$26.11$126,894.60View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/19/2016Lorin RandallDirectorSell1,488$28.68$42,675.84View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/4/2016Ian F. SmithDirectorSell13,231$41.85$553,717.35View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/23/2015Jane WasmaninsiderSell10,751$43.10$463,368.10View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/22/2015Lauren M. SabellainsiderSell7,113$42.04$299,030.52View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/21/2015Jane WasmanInsiderSell817$42.00$34,314.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/18/2015David LawrenceinsiderSell39,026$40.63$1,585,626.38View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/17/2015Lauren M. SabellainsiderSell14,229$40.00$569,160.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/1/2015Enrique J CarrazanaInsiderSell7,218$38.08$274,861.44View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/1/2015Ron CohenCEOSell11,850$38.08$451,248.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/19/2015Andrew BlightinsiderSell32,500$30.87$1,003,275.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/7/2015Michael W. RogersCFOSell5,700$30.24$172,368.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/5/2015Jane WasmaninsiderSell3,750$31.75$119,062.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/5/2015Ron CohenCEOSell135,000$28.03$3,784,050.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/21/2015Andrew BlightinsiderSell13,085$31.30$409,560.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/15/2015Andrew A HindmanInsiderSell4,779$29.82$142,509.78View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/12/2015Enrique J CarrazanaInsiderSell97,993$42.21$4,136,284.53View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/18/2014David LawrenceInsiderSell27,109$40.11$1,087,341.99View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/18/2014John P KelleyDirectorSell10,000$40.00$400,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/1/2014David LawrenceInsiderSell8,898$35.60$316,768.80View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/1/2014Lauren M SabellaVPSell3,242$35.58$115,350.36View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/1/2014Michael W RogersCFOSell230$35.58$8,183.40View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/1/2014Ron CohenCEOSell34,394$35.59$1,224,082.46View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/7/2014Michael W RogersCFOSell5,700$33.10$188,670.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/3/2014Jane WasmanInsiderSell3,750$34.13$127,987.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/24/2014Jane WasmanInsiderSell14,923$36.00$537,228.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/27/2014Jane WasmanInsiderSell14,923$33.00$492,459.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/5/2013Lauren SabellaVPSell8,797$31.81$279,832.57View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/2/2013Enrique CarrazanaInsiderSell1,640$33.56$55,038.40View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/15/2013Enrique J CarrazanaInsiderSell3,333$32.38$107,922.54View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/3/2013Jane WasmanInsiderSell3,750$35.74$134,025.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/20/2013Ron CohenCEOSell149,000$34.10$5,080,900.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/2/2013John KelleyDirectorSell15,000$38.00$570,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/19/2013Andrew BlightInsiderSell19,296$37.82$729,774.72View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/10/2013Ron CohenCEOSell11,000$34.15$375,650.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/8/2013Sandra Phd PanemDirectorSell10,000$33.80$338,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/4/2012Lauren M SabellaVPSell4,364$24.58$107,267.12View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/3/2012Andrew BlightInsiderSell7,200$24.20$174,240.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/3/2012David LawrenceCFOSell9,313$24.21$225,467.73View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/3/2012Ron CohenCEOSell16,407$24.22$397,377.54View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/13/2012Sandra Phd PanemDirectorSell22,569$24.12$544,364.28View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for Acorda Therapeutics (NASDAQ:ACOR)
DateHeadline
06/23/16 08:37 PMFull Federal Circuit Denies En Banc Review of Jurisdictional Decision with Important Implications for BPCIA Litigation
06/23/16 10:02 AMFull Fed. Circ. Won't Review Generics Jurisdiction Ruling
06/23/16 10:02 AMAcorda Therapeutics (ACOR) Says Court Denied Mylan's (MYL) Request for Rehearing
06/23/16 10:02 AMFirst Week of August 19th Options Trading For Acorda Therapeutics (ACOR)
06/21/16 02:15 PMFirst Week of August 19th Options Trading For Acorda Therapeutics (ACOR) - Nasdaq
06/21/16 02:15 PMAcorda Therapeutics (ACOR) Says Court Denied Mylan's (MYL) Request for Rehearing - StreetInsider.com
06/21/16 07:03 AMAcorda Therapeutics, Inc. (NASDAQ:ACOR) Current Analyst Ratings - Fiscal Standard
06/21/16 06:32 AMACORDA THERAPEUTICS INC Files SEC form 8-K, Other Events -
06/20/16 02:16 PMStrong Buy Calls Count For Acorda Therapeutics, Inc. (NASDAQ:ACOR) At 3 - Investor Newswire
06/20/16 02:16 PMCompany Shares of Acorda Therapeutics Drops by -4.88% - Trade Calls
06/20/16 02:16 PMAcorda Therapeutics, Inc. Stock Momentum Hits Weakness - CML News
06/17/16 10:12 AM7 Biotech Stocks that are Buys Right Now
06/15/16 07:04 AMDicerna Pharmaceuticals : Appoints Martin Freed, M.D., to Board of Directors
06/13/16 01:37 PMAcorda Therapeutics, Inc. – Value Analysis (NASDAQ:ACOR) : June 13, 2016 -
06/13/16 10:25 AMBIOTIE ANNOUNCES THAT THE DELISTING OF ITS ADS HAS BECOME EFFECTIVE
06/13/16 08:49 AMBiotie Therapies Corp. Announces That the Delisting of Its American Depositary Shares from NASDAQ Global Select Market Has Become Effective - [at noodls] - TURKU, Finland--(BUSINESS WIRE)-- Biotie Therapies Corp. (Nasdaq Helsinki: BTH1V) ('Biotie' or the 'Company') announces that the voluntary delisting of its American Depositary Shares ('ADSs') from the ...
06/11/16 07:44 PMForm 4 ACORDA THERAPEUTICS INC For: Jun 08 Filed by: PANEM SANDRA PHD - StreetInsider.com
06/11/16 10:27 AMAcorda Therapeutics : Pre-market Insights on Biotechnology Stocks -- BioMarin Pharma, Alexion Pharma, Aegerion Pharma, and Acorda Therapeutics
06/11/16 10:27 AMForm 4 ACORDA THERAPEUTICS INC For: Jun 08 Filed by: SMITH IAN F
06/10/16 07:58 PMTrend Of Rating Given To Acorda Therapeutics, Inc. (NASDAQ:ACOR) - Investor Newswire
06/10/16 10:40 AMForm 8-K ACORDA THERAPEUTICS INC For: Jun 08 - StreetInsider.com
06/10/16 10:40 AMForm 4 ACORDA THERAPEUTICS INC For: Jun 08 Filed by: SMITH IAN F - StreetInsider.com
06/10/16 07:22 AMAcorda Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : ACOR-US : June 10, 2016 -
06/10/16 06:42 AMACORDA THERAPEUTICS INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders -
06/09/16 10:45 AMAcorda Therapeutics (ACOR) Announces Presentation of CVT-427 Phase 1 PK Data; No Serious Events Noted - StreetInsider.com
06/09/16 08:30 AMThe Zacks Analyst Blog Highlights: Biogen, Merrimack Pharmaceuticals, Retrophin, Idera Pharmaceuticals and Acorda Therapeutics -
06/06/16 07:54 PMACORDA THERAPEUTICS INC. (NASDAQ:ACOR) Financial Condition Compared to S&P 500 - CML News
06/06/16 09:45 AMCelldex (CLDX) Presents Phase II Melanoma Study Data -
06/05/16 07:34 PMPerformance Review for Acorda Therapeutics, Inc. (NASDAQ:ACOR) - HNN
06/05/16 02:17 PMHow Many Acorda Therapeutics Inc (NASDAQ:ACOR)'s Analysts Are Bearish? - HNN
06/04/16 10:44 AMAnalysts Update on Stocks: Acorda Therapeutics, Inc. (NASDAQ:ACOR) , Spark Therapeutics, Inc. (NASDAQ:ONCE) - Street Updates
06/03/16 10:44 AMBRIEF-Acorda Therapeutics says on June 1 entered credit agreement with units - SEC filing - Reuters
06/03/16 10:44 AMAcorda Therapeutics Inc (ACOR) Given New $52.00 Price Target at Aegis - Let Me Know About This
06/02/16 02:17 PMForm 8-K ACORDA THERAPEUTICS INC For: Jun 01 - StreetInsider.com - Form 8-K ACORDA THERAPEUTICS INC For: Jun 01StreetInsider.comOn June 1, 2016, Acorda Therapeutics, Inc. (the “Company” and “we,” “us” or “our”) and certain of its subsidiaries entered into a Credit Agreement (the “Credit Agreement”) with JPMorgan Chase Bank, N.A., as the sole initial lender and the ...BRIEF-Acorda Therapeutics says on June 1 entered credit agreement with units - SEC filingReutersall 2 news articles »
06/02/16 07:49 AMBRIEF-Acorda Therapeutics says on June 1 entered credit agreement with units - SEC filing - * On June 1, co, units entered into a credit agreement - SEC filing
06/02/16 06:35 AMACORDA THERAPEUTICS INC Files SEC form 8-K, Creation of a Direct Financial Obligation or an Obligation under an Off-B -
06/01/16 10:37 AMStock Review and Earnings Check on Acorda Therapeutics, Inc. (NASDAQ:ACOR) - HNN - Stock Review and Earnings Check on Acorda Therapeutics, Inc. (NASDAQ:ACOR)HNNInvestors and analysts are typically super focused on company earnings numbers when they are reported. Company earnings are a good way to evaluate the company profitability. Currently, sell-side analysts are expecting Acorda Therapeutics, Inc.and more »
06/01/16 10:37 AMAcorda Therapeutics Inc. (ACOR) is Trading Higher on Unusual Volume for May 30 - Equities.com - Acorda Therapeutics Inc. (ACOR) is Trading Higher on Unusual Volume for May 30Equities.comAcorda Therapeutics Inc. (ACOR) experienced unusually high volume on May. 30, as the stock gained 1.53% to a closing price of $27.29. The stock saw 908,524 shares trade hands over the course of the day on 5,104 trades. Given that the stock's average ...and more »
05/31/16 02:16 PMStock Paining Investors: Acorda Therapeutics, Inc. (NASDAQ:ACOR) - HNN - Stock Paining Investors: Acorda Therapeutics, Inc. (NASDAQ:ACOR)HNNWhen a company shows a steady upwards earnings trend, it is a good indicator that the company will dominate companies with a more volatile earnings trend. Acorda Therapeutics, Inc. (NASDAQ:ACOR)'s trailing 12 months EPS is 0.31. Last year, their EPS ...and more »
05/31/16 02:16 PMTraders Observing Biotech Stocks: Teva Pharmaceutical Industries Limited (NYSE:TEVA) , Acorda Therapeutics, Inc ... - Is stories - Traders Observing Biotech Stocks: Teva Pharmaceutical Industries Limited (NYSE:TEVA) , Acorda Therapeutics, Inc ...Is storiesTeva Pharmaceutical Industries Limited (NYSE:TEVA) increased +0.14% to $51.66 while traded 3.71 million shares on 5/27/2016. The stock price negotiated for value between $51.56 to $52.45 in recent trading session. During the past 52 weeks, the stock's ...and more »
05/31/16 02:16 PMAcorda Therapeutics to Present at the 37th Annual Goldman Sachs Global Healthcare Conference - Business Wire (press release) - Acorda Therapeutics to Present at the 37th Annual Goldman Sachs Global Healthcare ConferenceBusiness Wire (press release)ARDSLEY, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics, Inc. (Nasdaq:ACOR) announced that Michael Rogers, Chief Financial Officer, will present at the Goldman Sachs Global Healthcare Conference on Tuesday, June 7 at 2:00pm PT (5:00pm ET).and more »
05/31/16 06:22 AMAcorda Therapeutics to Present at the 37th Annual Goldman Sachs Global Healthcare Conference - [at noodls] - ARDSLEY, N.Y.--(BUSINESS WIRE)-- Acorda Therapeutics, Inc. (Nasdaq:ACOR) announced that Michael Rogers, Chief Financial Officer, will present at the Goldman Sachs Global Healthcare Conference on Tuesday, ...
05/30/16 08:15 AMStock Rating Review for Acorda Therapeutics, Inc. (NASDAQ:ACOR) - HNN - Stock Rating Review for Acorda Therapeutics, Inc. (NASDAQ:ACOR)HNNInvestors may choose to follow the views of professional Wall Street analysts that regularly track the company. Covering equity analysts presently have a consensus stock rating of 2 on shares of Acorda Therapeutics, Inc. (NASDAQ:ACOR). Covering ...and more »
05/27/16 01:45 PMThe Medicines Co. Carbavance TANGO 1 Study Enrolled -
05/27/16 08:04 AMAlkermes Plc (NASDAQ:ALKS) Begins New Study As Acorda Therapeutics, Inc. (NASDAQ:ACOR) Discontinues Theirs - Market Exclusive - Market ExclusiveAlkermes Plc (NASDAQ:ALKS) Begins New Study As Acorda Therapeutics, Inc. (NASDAQ:ACOR) Discontinues TheirsMarket ExclusiveAs Alkermes begins a study on its immuno-oncology drug, Acorda is closing a chapter on its PLUMIAZ Nasal Spray. Acorda began studying this spray to help in the treatment of epilepsy. Now, the study is no more as focus is being shifted elsewhere. The ...and more »
05/26/16 05:06 PMNoteworthy Two Stocks to Observe: Acorda Therapeutics, Inc. (NASDAQ:ACOR) , ABIOMED, Inc. (NASDAQ:ABMD) - Street Updates - Noteworthy Two Stocks to Observe: Acorda Therapeutics, Inc. (NASDAQ:ACOR) , ABIOMED, Inc. (NASDAQ:ABMD)Street UpdatesOn 5/25/2016, shares of Acorda Therapeutics, Inc. (NASDAQ:ACOR) fell -1.38% in trading session and finally closed at $27.21. The company most recent volume stood at 425.89 thousand shares as compared to its average volume of 800.89 thousand shares ...
05/26/16 10:30 AMAlkermes Begins Phase I Study on Immuno-Oncology Drug -
05/25/16 08:16 AMEarnings Review and Stock Rundown for Acorda Therapeutics, Inc. (NASDAQ:ACOR) - Wall Street Hints and News - Earnings Review and Stock Rundown for Acorda Therapeutics, Inc. (NASDAQ:ACOR)Wall Street Hints and NewsInvestors and analysts will be paying close attention when the company posts earnings results. Earnings numbers can provide insight into a company's overall profitability. Covering equity analysts are expecting Acorda Therapeutics, Inc. (NASDAQ:ACOR ...Hold Calls Count For Acorda Therapeutics, Inc. (NASDAQ:ACOR) At 3Investor Newswireall 206 news articles »
05/25/16 07:03 AMAcorda Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : ACOR-US : May 25, 2016 -
05/23/16 05:04 PMHold Calls Count For Acorda Therapeutics, Inc. (NASDAQ:ACOR) At 3 - Investor Newswire - Hold Calls Count For Acorda Therapeutics, Inc. (NASDAQ:ACOR) At 3Investor NewswireBuy calls count on Acorda Therapeutics, Inc. (NASDAQ:ACOR)'s stock stands at 0 while Sell recommendations is 0. Hold recommendation is 3. Acorda Therapeutics, Inc. (NASDAQ:ACOR) has a total of 3 Strong Buy recommendations and 0 Strong Sell ...and more »
About Acorda Therapeutics

Acorda Therapeutics logoAcorda Therapeutics, Inc. is a biopharmaceutical company engaged in the identification, development and commercialization of therapies that restore neurological function and treat patients with neurological disorders. The Company's markets three United States Food and Drug Administration (FDA)-approved therapies, including Ampyra (dalfampridine) Extended Release Tablets, 10milligrams, a treatment to improve walking in patients with multiple sclerosis (MS). It also markets Zanaflex Capsules and tablets, FDA-approved as short-acting drugs for the management of spasticity, and Qutenza, an FDA-approved dermal patch for the management of neuropathic pain associated with post-herpetic neuralgia, also known as post-shingles pain. The Company is also developing a number of clinical and preclinical stage therapies for the treatment of a range of disorders, including chronic post-stroke walking deficits (PSWD), Parkinson's disease, epilepsy, heart failure, MS, and spinal cord injury.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: ACOR
  • CUSIP: 00484M10
Key Metrics:
  • Previous Close: $26.31
  • 50 Day Moving Average: $26.85
  • 200 Day Moving Average: $32.12
  • P/E Ratio: 83.58
  • P/E Growth: 1.18
  • Market Cap: $1.16B
  • Current Quarter EPS Consensus Estimate: $0.74 EPS
Additional Links:
Acorda Therapeutics (NASDAQ:ACOR) Chart for Saturday, June, 25, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha